AstraZeneca PLC (AZN)vsMonster Beverage Corp (MNST)
AZN
AstraZeneca PLC
$185.78
+0.93%
HEALTHCARE · Cap: $284.63B
MNST
Monster Beverage Corp
$73.21
+0.29%
CONSUMER DEFENSIVE · Cap: $71.62B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 608% more annual revenue ($58.74B vs $8.29B). MNST leads profitability with a 23.0% profit margin vs 17.4%. AZN appears more attractively valued with a PEG of 1.50. MNST earns a higher WallStSmart Score of 68/100 (B-).
AZN
Strong Buy66
out of 100
Grade: B-
MNST
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$185.78
$120.29 discount
Margin of Safety
+11.0%
Fair Value
$90.79
Current Price
$73.21
$17.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Strong operational efficiency at 31.3%
Earnings expanding 66.6% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 27 in profit
Keeps 23 of every $100 in revenue as profit
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 8.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : MNST
The strongest argument for MNST centers on Operating Margin, EPS Growth, Altman Z-Score. Profitability is solid with margins at 23.0% and operating margin at 31.3%. Revenue growth of 17.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : MNST
The primary concerns for MNST are PEG Ratio, P/E Ratio, Price/Book.
Key Dynamics to Monitor
AZN profiles as a value stock while MNST is a growth play — different risk/reward profiles.
MNST carries more volatility with a beta of 0.44 — expect wider price swings.
MNST is growing revenue faster at 17.6% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
MNST scores higher overall (68/100 vs 66/100), backed by strong 23.0% margins and 17.6% revenue growth. AZN offers better value entry with a 32.8% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Monster Beverage Corp
CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA
Monster Beverage Corporation is an American beverage company that manufactures energy drinks including Monster Energy, Relentless and Burn.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?